Letzte Aktualisierung
Aktuelle Neuigkeiten
PRESSEMITTEILUNG HGF stärkt seine Präsenz in Europa mit drei neuen Partnern in Frankreich und Deutschland
HGF stärkt seine Präsenz in Europa mit drei neuen Partnern in Frankreich und Deutschland HGF freut sich, die Aufnahme von drei neuen Partnern bekannt zu geben, die die Präsenz des …
WeiterlesenG1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.
Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …
WeiterlesenDie Beschwerdekammer des EPA äußert sich zum Umfang des Ausschlusses der Sittenwidrigkeit von der Patentierbarkeit
Die jüngste Entscheidung T1553/22 der Beschwerdekammer verpflichtete die Kammer, den Umfang der Ausschlüsse von der Patentierbarkeit gemäß Artikel 53(a) EPÜ zu prüfen. Die Erfindung in diesem Fall bezog sich auf …
Weiterlesen
Welcome to HGF Presents – New Video Series
Introducing HGF Presents a new video series delivering practical insights into European Patent Law and practice. Curated by our leading experts in chemistry, life sciences, technology & engineering, each concise …
WeiterlesenSeminar on Incorporating Trade Secrets into your IP Strategy
HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …
Weiterlesen
Providing Enabling Disclosure for AI inventions at the EPO
Video overview: The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications …
Weiterlesen
Personalised Medicine Patenting of Known Drugs for Known Indications at the EPO
Video overview: The identification of specific sub-groups of patients to treat with a known drug, even if said patients may have been treated before with the drug, can yield patentable …
Weiterlesen
Novelty Over Clinical Trials at the EPO
Video overview: Second medical use claims can be novel over clinical trials in European patents. Typically, such a claim would be fairly narrow, e.g. perhaps mapping onto specific indications and …
Weiterlesen
Regulatory Exclusivity for Medicinal Products in Europe
Video overview: New Medical Products 8 years of data exclusivity, followed by 2 years of market exclusivity. +1 year market exclusivity possible for a new indication showing significant clinical benefit. No exclusivity granted for new formulations or routes of …
Weiterlesen
Added Matter – Part 2
Video overview: Pre and Post-Grant Amendments are governed by Articles 123(2) & 123(3) EPC respectively Before grant, amendments can broaden the claim scope as long as the resulting claim is …
Weiterlesen
Added Matter – Part 1
Video overview: What is Added Matter? Added matter occurs when an amendment introduces content that goes beyond what was originally disclosed in the application as filed (Article 123(2) EPC). EPO …
Weiterlesen